The treatment with Dara in MM patients has been shown to modulate anti‐tumour T cell response by reducing CD38+ regulatory T cells (Tregs) and expanding CD3+ T cells (CD8+ T cells in particular) with a skewed T cell repertoire.24, 25, 26, 27, 28. This evidence concerns the gene CD38 and Miyoshi myopathy.